MIR223: MIR223 is a microRNA that has been found to play a role in various biological processes. In MIR223 deficient mice, an increase in granulocyte numbers and abnormal phenotype has been observed, leading to the development of inflammatory lung pathology [PMC7871001]. Microarray analyses have shown that MIR223 is enriched in microglia [PMC6351131]. Another short RNA, MIR223 derived from thrombin activated PL-EVs, has been found to regulate the endothelial expression of FBXW7 and EFNA1 mRNA targets [PMC8468534]. While upregulation of MIR223 in peripheral plasma has been reported, its expression was significantly decreased in SLE patients with active nephritis [PMC7871001]. CircMTO1 was found to act as a sponge for both miR9 and MIR223 [PMC7093694]. In hepatocellular carcinoma (HCC), MIR223 levels are depleted in tissues but its concentration rises in serum, suggesting its potential as a serum biomarker for HCC [PMC4581219]. Mutated rs3750996 was reported to affect the binding affinity of MIR223 but further investigations are needed to determine its influence on STIM1 gene expression [PMC7767290]. Deregulated miRNAs such as miR199-214, miR371-373, and MIR223 have been implicated in various cellular processes including tumor metabolism, p53 pathway regulation, cell cycle regulation, Wnt/β-catenin signaling, apoptosis and cell growth through FBXW7 [PMC9495386]. In the miRNA-mediated synaptic plasticity regulating pathway, MIR501 targets GluR1 while both MIR223 and miR134 target GluR2 and NR2B respectively [PMC4783348].